Developer of an intelligent automation technology designed to improve the healthcare revenue cycle.
Developer of an intelligent automation technology designed to improve the healthcare revenue cycle.
Enterprise Systems (Healthcare)📍 San Francisco, CAFounded 2018
Current Valuation
$1.0B
as of 2022-Q1
UNICORN
QL Price
$609.89M
-40% vs last round
QuantLogix's current estimate for AKASA, published 2026-09-27 — below the last disclosed round of $1.0B (2022-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.0B
2022-Q1
weight 0.04
Secondary market print
$578.34M
2026-06-27
weight 0.58
How this price has held up
No round has priced for AKASA since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, AKASA, 2026-09-27 (1e8e6057652862af).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is AKASA going public?
No. AKASA is private and has not filed to go public. There is no S-1 on file.
What is AKASA's valuation in 2026?
AKASA is valued at $1.0B as of 2022-Q1, set by its Series C ($120M, Feb 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has AKASA filed an S-1?
No public S-1 is on file for AKASA.
How much has AKASA raised?
AKASA has raised $205M in total, most recently a Series C of $120M in Feb 2022.
Is AKASA publicly traded — can you buy AKASA stock?
No. AKASA is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for AKASA on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2018
HQ
San Francisco, CA
Employees
200
Total Raised
$205M
Last Round
Series C — $120M (Feb 2022)
IPO Status
private
Fundraising Status
Series C · $120M · 4y 7mo ago
privateTotal raised $205M
Secondary Market
Implied price / share
$20
Last round price / share
$35.3
vs last round
-43.3%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$120M
Feb 2022
—
$1.0B
Vertical Intelligence — AI / ML
No verified Hugging Face organization found for AKASA — no attributable open-model footprint. Closed-weights labs are common; this is a distribution signal, not a capability judgment.
Checked huggingface.co as of 2026-09-18. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
-8% vs 2026-08
Open roles
11
via ashby
Product-build share
55%
engineering, research, product, design
Trajectory
steady
product-led hiring — 55% of open roles build product; the rest are go-to-market and G&A.
Counted from AKASA's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareMachine LearningArtificial Intelligence
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q1. Refreshed quarterly.